283 related articles for article (PubMed ID: 25676487)
1. Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib.
Peng L; Ye X; Zhou Y; Zhang J; Zhao Q
Support Care Cancer; 2015 Sep; 23(9):2813-24. PubMed ID: 25676487
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of subcutaneous versus intravenous bortezomib in multiple myeloma: a meta-analysis
.
Hu B; Zhou Q; Wu T; Zhuang L; Yi L; Cao J; Yang X; Wang J
Int J Clin Pharmacol Ther; 2017 Apr; 55(4):329-338. PubMed ID: 28079515
[TBL] [Abstract][Full Text] [Related]
3. [Incidence and Risk of Peripheral Neuropathy Caused by Intravenous and Subcutaneous Injection of Bortezomib].
Liu ZQ; Xia HL; Li CJ; Xia L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Oct; 27(5):1654-1663. PubMed ID: 31607328
[TBL] [Abstract][Full Text] [Related]
4. Incidence and risk of peripheral neuropathy with nab-paclitaxel in patients with cancer: a meta-analysis.
Peng L; Bu Z; Ye X; Zhou Y; Zhao Q
Eur J Cancer Care (Engl); 2017 Sep; 26(5):. PubMed ID: 26537178
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and risk factors of bortezomib induced peripheral neuropathy: A systematic review of phase III trials.
Li T; Timmins HC; King T; Kiernan MC; Goldstein D; Park SB
Hematol Oncol; 2020 Aug; 38(3):229-243. PubMed ID: 31873944
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.
Broyl A; Corthals SL; Jongen JL; van der Holt B; Kuiper R; de Knegt Y; van Duin M; el Jarari L; Bertsch U; Lokhorst HM; Durie BG; Goldschmidt H; Sonneveld P
Lancet Oncol; 2010 Nov; 11(11):1057-65. PubMed ID: 20864405
[TBL] [Abstract][Full Text] [Related]
7. Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial.
Merz M; Salwender H; Haenel M; Mai EK; Bertsch U; Kunz C; Hielscher T; Blau IW; Scheid C; Hose D; Seckinger A; Jauch A; Hillengass J; Raab MS; Schurich B; Munder M; Brossart P; Gerecke C; Lindemann HW; Zeis M; Weisel K; Duerig J; Goldschmidt H
Haematologica; 2016 Dec; 101(12):e485-e487. PubMed ID: 27540135
[No Abstract] [Full Text] [Related]
8. Subcutaneous versus Intravenous Bortezomib Administration for Multiple Myeloma Patients: a Meta-analysis.
Mu SD; Ai LS; Qin Y; Hu Y
Curr Med Sci; 2018 Feb; 38(1):43-50. PubMed ID: 30074150
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of bortezomib maintenance in patients with newly diagnosed multiple myeloma: a meta-analysis.
Sun CY; Li JY; Chu ZB; Zhang L; Chen L; Hu Y
Biosci Rep; 2017 Aug; 37(4):. PubMed ID: 28706008
[TBL] [Abstract][Full Text] [Related]
10. Impact of Body Mass Index on the Incidence of Bortezomib-induced Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma.
Moore DC; Ringley JT; Nix D; Muslimani A
Clin Lymphoma Myeloma Leuk; 2020 Mar; 20(3):168-173. PubMed ID: 32029398
[TBL] [Abstract][Full Text] [Related]
11. Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data.
Maschio M; Zarabla A; Maialetti A; Marchesi F; Giannarelli D; Gumenyuk S; Pisani F; Renzi D; Galiè E; Mengarelli A
Integr Cancer Ther; 2018 Dec; 17(4):1115-1124. PubMed ID: 30295079
[TBL] [Abstract][Full Text] [Related]
12. [Management of proteasome inhibitor-induced peripheral neuropathy].
Takamatsu Y
Nihon Rinsho; 2015 Jan; 73(1):137-41. PubMed ID: 25626319
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy.
Minarik J; Pavlicek P; Pour L; Pika T; Maisnar V; Spicka I; Jarkovsky J; Krejci M; Bacovsky J; Radocha J; Straub J; Kessler P; Wrobel M; Walterova L; Sykora M; Obernauerova J; Brozova L; Gregora E; Adamova D; Gumulec J; Adam Z; Scudla V; Hajek R;
PLoS One; 2015; 10(4):e0123866. PubMed ID: 25875484
[TBL] [Abstract][Full Text] [Related]
14. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
Richardson PG; Briemberg H; Jagannath S; Wen PY; Barlogie B; Berenson J; Singhal S; Siegel DS; Irwin D; Schuster M; Srkalovic G; Alexanian R; Rajkumar SV; Limentani S; Alsina M; Orlowski RZ; Najarian K; Esseltine D; Anderson KC; Amato AA
J Clin Oncol; 2006 Jul; 24(19):3113-20. PubMed ID: 16754936
[TBL] [Abstract][Full Text] [Related]
15. [Prophylaxis of Bortezomib-Induced Peripheral Neuropathy in Patients with Multiple Myeloma by High-Dose Intravenous Mecobalamin].
Zhang LL; Wang YH; Shao ZH; Ma J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):480-484. PubMed ID: 28446297
[TBL] [Abstract][Full Text] [Related]
16. Incidence and relative risk of peripheral neuropathy in cancer patients treated with eribulin: a meta-analysis.
Peng L; Hong Y; Ye X; Shi P; Zhang J; Wang Y; Zhao Q
Oncotarget; 2017 Dec; 8(67):112076-112084. PubMed ID: 29340112
[TBL] [Abstract][Full Text] [Related]
17. Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma.
Kumar SK; Laubach JP; Giove TJ; Quick M; Neuwirth R; Yung G; Rajkumar SV; Richardson PG
Br J Haematol; 2017 Sep; 178(5):756-763. PubMed ID: 28591409
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib for patients with previously untreated multiple myeloma: a systematic review and meta-analysis of randomized controlled trials.
Zeng Z; Lin J; Chen J
Ann Hematol; 2013 Jul; 92(7):935-43. PubMed ID: 23455401
[TBL] [Abstract][Full Text] [Related]
19. A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma.
Magrangeas F; Kuiper R; Avet-Loiseau H; Gouraud W; Guérin-Charbonnel C; Ferrer L; Aussem A; Elghazel H; Suhard J; Sakissian H; Attal M; C Munshi N; Sonneveld P; Dumontet C; Moreau P; van Duin M; Campion L; Minvielle S
Clin Cancer Res; 2016 Sep; 22(17):4350-4355. PubMed ID: 27060151
[TBL] [Abstract][Full Text] [Related]
20. Investigation of the frequency of bortezomib neuropathy in patients with multiple myeloma diagnosis with normal and abnormal genetic characteristics.
Kul AN; Ipek Y
J Oncol Pharm Pract; 2023 Oct; 29(7):1652-1660. PubMed ID: 36237141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
